Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation

• Takamatsu, Hiroyuki

• Araki, Raita

• Nishimura, Ryosei

• Yachie, Akihiro

• Espinoza, J. Luis

• Okumura, Hirokazu

• Yoshida, Takashi

• Kuzushima, Kiyotaka

• Nakao, Shinji

Abstract

Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load. © 2016 Elsevier B.V.

Embargo Period 12 months

Journal

• Journal of Clinical Virology

  Journal of Clinical Virology 80 82-86, 2016-06-01

  Elsevier

Keywords

• Cidofovir
• Donor lymphocyte infusion
• Epstein-Barr virus
• Post-transplant lymphoproliferative disease
• Rituximab

Details

• CRID: 1050282810927837184
• NII Article ID: 120005771106
• NII Book ID: AA11281494
• ISSN: 13866532
• Web Site: http://hdl.handle.net/2297/45519
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • CiNii Articles